Locus raises $19M to take CRISPR-based antimicrobial ‘Pac-Man’ into clinic – FierceBiotech
FierceBiotech |
Locus raises $19M to take CRISPR-based antimicrobial 'Pac-Man' into clinic
FierceBiotech There are plenty of companies looking at using the gene-editing technology CRISPR-Cas9 to treat human diseases, but Locus is the only company in the world using a different pathway—CRISPR-Cas3—to tackle the pressing problem of multidrug-resistant … Locus Biosciences Closes $19 Million Series A Led by ARTIS Ventures for CRISPR-Cas3 Antimicrobials |
